Arcturus Therapeutics Holdings (ARCT) Change in Accured Expenses (2018 - 2026)

Arcturus Therapeutics Holdings' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 85.04% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 77.53% YoY) and the FY2025 annual result came in at -$15.3 million, down 357.33% from the prior year.
• Change in Accured Expenses was -$1.2 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $4.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $9.4 million in Q2 2022 and bottomed at -$8.2 million in Q1 2025.
• A 5-year average of -$100647.1 and a median of -$454000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 178.73% — and 2025, when it slumped 2174.66%.
• Arcturus Therapeutics Holdings' Change in Accured Expenses stood at $7.4 million in 2022, then slumped by 61.65% to $2.8 million in 2023, then surged by 130.15% to $6.6 million in 2024, then slumped by 32.09% to $4.5 million in 2025, then tumbled by 127.69% to -$1.2 million in 2026.
• Business Quant data shows ARCT's Change in Accured Expenses at -$1.2 million in Q1 2026, $4.5 million in Q4 2025, and -$5.4 million in Q3 2025.